This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
India’s pharmaceutical market, currently valued at approximately $60 billion, is projected to double by 2030. Getting this right will hold the key to winning a disproportionate market share in a large and expanding value pool (~$12B domestic market for global pharma companies by 2030).
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? July 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The focus of the investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca.
Singh attributes this decline to a mix of global and local challenges, “The slowdown is likely driven by a mix of global pricing pressures, regulatory shifts, and changing export dynamics, including stricter scrutiny of pharmaceutical exports from India and adjustments in domestic drugpricing policies.”
Image Credit: Adobe Stock Images/StockMediaLabs.com Evaluate, who provides market insights for the pharma industry, has unveiled its “2025 World Preview Report,” which offers insights for the global pharmaceutical market through the year 2030. They are also expected make up close to 9% of all Rx drug sales by the end of the decade.
This includes initiatives such as ATMP 2030 led out of Sweden. While there may be economy in scale, the challenge is to model how new drugs on the market will be valued. There needs to be balance, especially for a global marketing strategy where drugprices are historically higher in regions such as the US to that of Europe.
Tariffs on China will make generic drugprices go up I assume because China is such an important supplier of active pharmaceutical ingredients, as well as finished products.” 13 The president believes that that the order could help decrease drugprices by 30% to 80%. Pharmaceutical Commerce. February 5, 2025. Saraceno N.
The tariff is meant to encourage pharma manufacturers to reshore their production back to the United States, which has been in the works for many players, including AstraZeneca, who plans to invest $50 billion by 2030 in US-based drug manufacturing and R&D, marking its largest single manufacturing investment globally.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drugprices? The opinions reflect the strength of the clinical evidence and the potential of long-acting innovations like lenacapavir to address real-world barriers to the use of PrEP.
Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. LanKS via Shutterstock.
AstraZeneca will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030. billion announced in November of last year, 1 it will be investing $50 billion in the United States by the year 2030.
The goal is to take annual bilateral trade between the two nations to $500 billion by 2030 from the current $190 billion. Generic products already enter the market at a lower price than the originator, so India is effectively offering a financial incentive that the US could accept, given its reliance on Indian-manufactured generics.
How Recent Executive Orders Impact the DrugPricing Landscape Nicholas Saraceno, Editor May 30th 2025 Podcast Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drugpricing and market access.
Companies such as AstraZeneca are committing massive investments, including $50 billion in US manufacturing and R&D by 2030, to strengthen domestic production and mitigate tariff impacts. It will also support our ambition to reach $80 billion in revenue by 2030. Trump Says Pharma Industry Should Expect Tariffs by Aug. Saraceno N.
This could transform the current drugpricing model, shifting from regular doses over time to a single treatment. Oncology already dominates the space, which is expected to continue to 2030 and account for 51.6% of the market at $8.1bn by 2030, followed by haematological disorders worth $5.4bn at 7.1%
The deal also supports its “Strategy 2030” plan, which highlights the value of temperature-controlled networks; first and last mile specialty courier coverage; and integrated solutions.
Chugai president and CEO Dr Osamu Okuda stated: “We believe that open innovation with external partners, including leading global players, is extremely important for achieving global first-class drug discovery outlined in our growth strategy toward 2030, TOP I 2030. “By How will RFK Jr’s American dream for vaccines play out?
Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster. The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData.
GlobalData’s Pharma Intelligence Center forecasts global sales for the drug to peak in 2030, generating $7bn in revenue. How will RFK Jr’s American dream for vaccines play out? With entry to the market, Imfinzi stands alone as the only perioperative immunotherapy for muscle-invasive bladder cancer.
Analysts predict that adding duties to incoming goods will likely elevate costs across the pharmaceutical value chain, ultimately raising drugprices for patients. The policies make for interesting analysis when combined with his desire to cut prescription prices in the country.
… Roche warned that President Trump’s executive order on drugpricing threatens its planned $50 billion investment in the United States , Reuters writes. The order directs drugmakers to lower prices of brand-name medicines to align with those in other wealthy nations. Best of luck, everyone.
The study projects that if the funding interruption persists, Mozambique could see a 15% rise in HIV infections and a 10% increase in HIV-related deaths by the year 2030. How will RFK Jr’s American dream for vaccines play out?
Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Plenty of people in pharma and at the banks that invest in it seem to think so. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.
And you know why: Demand is intense — so intense that, by 2030, the market for these medicines is forecast to hit $41 billion, according to analysts at TD Cowen. The fundamental issues and intriguing stories that characterized the year gone by will to continue to loom.
In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.
1 segment on the widely watched CBS News program about the Novo Nordisk drug, which is on its way to becoming a top-selling medicine and has experienced shortages due to high demand. Wegovy is one of a few treatments that are expected to transform weight-loss medicines into a $30 billion market by 2030, according to analysts at Cowen.
… Investors in biopharma companies, who lobbied vigorously — but unsuccessfully — against allowing Medicare to negotiate drugprices, are trying a new tactic to preserve their profits , The Boston Globe tells us. and reduce HIV infections in the country by 90% by 2030.
Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToShow":2,
Regulatory Landscape Prior to 1984, generic drugs were required to undergo the same level of scrutiny as the drugs they were intended to substitute. In 1984, Congress passed the DrugPrice Competition and Patent Term Restoration Act, more commonly known as the Hatch Waxman Act.
Op-ed: IRA DrugPrice Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.
Op-ed: IRA DrugPrice Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.
Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
The new Abivax studies have pushed obefazimod to the front of the field for oral drugs that treat inflammatory bowel disease, Leerink Partners analyst Thomas J. The market for IBD, which includes both ulcerative colitis and Crohn’s disease, will reach $30 billion by 2030, Smith’s team at Leerink estimates. TechTarget, Inc.s
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs.
Drugprices crash post-patent loss, due to this competition, which is good for patients but leaves drug makers struggling with thin profit margins. India’s traditional strength lies in small molecule chemical-based drugs which is why not too many companies focus on biologics.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content